Zoom Logo

Tisch Cancer Institute Seminar Series - Shared screen with speaker view
Amaia.Lujambio@mssm.edu
29:51
You can type the questions in this section
Amaia.Lujambio@mssm.edu
58:09
You can post your questions for Augusto here
Alice Kamphorst
01:00:21
He shows depleted vs enriched, but did he tried on bulk ( not depleted or enriched?)
Kenan Onel
01:05:22
For the liquid biopsy ctDNA data, do you see differences between patients with single vs multiple lesions? In other words, how does intra-individual tumor heterogeneity alter the signal?
Julio
01:07:26
Augusto, during CR in those two patients were you guys able to detect ctDNA or only at relapse?
Bojan Losic
01:11:55
Augusto, did the cTDNA mutation profile match that of a typical HCC? i.e., were there other mutations with unexpected frequency?
Navneet Dogra
01:13:05
Is blood or urine better for liver biopsy
Natasha Kyprianou
01:13:13
Will DNA Methylation profile potentially become a routine analysis for clinical screening in liver
Abigail Lubin
01:15:45
What type of cells were used for the protein pull downs?
Matthew Lin
01:24:50
Sigma receptor needed for viral entry or viral replication? What is normal function for SR?
Bojan Losic
01:25:32
Are you thinking of trying two compounds to assess if synergistic effects exist?
Kenan Onel
01:25:48
Also, how many cell types are you using? Are you testing in lung cells?
Navneet Dogra
01:27:39
Is the virus isolated and concentrated before infection? If so, then how?
cderossi
01:28:43
do you have any studies ongoing looking at/targeting viral glycosylation?
Aneel Aggarwal
01:30:43
Hod does Remdesivir look in your assay?
kris
01:31:11
It is to be tested in the next round of screening